Vbi Vaccines Stock News

VBI Vaccines has not been immune to sell-off with their share price shrinking by roughly 75% over the past year despite the company making significant headway both clinically and commercially. VBIV is

The stock price of VBI Vaccines (VBIV) fell by 10.72% after hours in the most recent trading session. This is why.

Healthcare has become a bona fide stock picker's market this year.

Check these three biotech penny stocks out for your watchlist right now The post 3 Biotech Penny Stocks That Climbed in After-Hours Trading appeared first on Penny Stocks to Buy, Picks, News and Infor

VBI Vaccines recently reported updated data from their VBI-1901 candidate in recurrent Glioblastoma. The company publicized the median overall survival and 18-month overall survival data are outperfor

VBI Vaccines press release (VBIV): FY GAAP EPS of $0.27 beats by $0.54.Revenue of $0.63M (-40.6% Y/Y) misses by $0.17M.As of December 31, 2021 cash, cash equivalents…

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 40.88%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines (VBIV) is trading ~3% higher in the premarket Friday after the commercial stage vaccine maker announced that an expert panel of the European Medicines Agency ((EMA)) issued…

Cambridge, Massachusetts-based vaccine maker VBI Vaccines (VBIV) announced on Wednesday that an expert panel of the U.S

During the last session, VBI Vaccines Inc. (NASDAQ:VBIV)’s traded shares were 1.85 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.44, reflecting an intraday loss of -5.88% or -$0.09. The 52-week high for the VBIV share is $4.31, that puts it down … VBI Vaccines Inc. (NASDAQ: VBIV)’s Stock Is Down -60.98% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 Read More »

VBI Vaccines Inc. (VBIV) shares closed today at 1.4% above its 52 week low of $2.09, giving the company a market cap of $545M. The stock is currently down 9.4% year-to-date, down 34.2% over the past 12 months, and down 37.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 31.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -24.7% The company's stock price performance over the past 12 months beats the peer average by -15.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Los Angeles, USA, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Glioblastoma Pipeline Analysis | Clinical Trials Report 2021 | DelveInsight There are approximately 150+ key companies developing Glioblastoma therapies. The companies with Glioblastoma drug candidates in the most advanced stage are Kintara Therapeutics, Diffusion Pharmaceuticals, Celgene Corporation, Bio-Thera Solutions. DelveInsight''s " Glioblastoma Pipeline Insight " report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Glioblastoma pipeline landscapes. It comprises Glioblastoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Glioblastoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Glioblastoma pipeline products. Some of the key takeaways from the Glioblastoma Pipeline Report Major companies such as Celgene Corporation, Myeloid Therapeutics, Genenta Science, Inovio Pharmaceuticals, Apogenix, Oncoceutics, Laminar Pharmaceuticals, Celgene Corporation, Bristol-Myers Squibb, Kintara Therapeutics, Kazia Therapeutics, Oncotelic Therapeutics, AstraZeneca, Genentech, Accendatech, Pfizer, Curtana Pharmaceuticals, Crimson BioPharm, Hope Biosciences, and others are developing potential drug candidates to improve the Glioblastoma treatment scenario.

VBI Vaccines Inc. (NASDAQ:VBIV)s stock price hit a new 52-week low on Friday following insider selling activity. The company traded as low as $2.45 and last traded at $2.46, with a volume of 54147 shares traded. The stock had previously closed at $2.71. Specifically, major shareholder Perceptive Advisors Llc sold 2,707,463 shares of the businesss []

VBI Vaccines Inc. (NASDAQ:VBIV)s share price reached a new 52-week low during trading on Friday . The stock traded as low as $2.45 and last traded at $2.46, with a volume of 54147 shares changing hands. The stock had previously closed at $2.71. Separately, Zacks Investment Research cut shares of VBI Vaccines from a buy []